Dsc Advisors Lowers stake in Amgen (AMGN)

Amgen (AMGN) : Dsc Advisors reduced its stake in Amgen by 0.48% during the most recent quarter end. The investment management company now holds a total of 15,303 shares of Amgen which is valued at $2,647,725 after selling 74 shares in Amgen , the firm said in a disclosure report filed with the SEC on Aug 15, 2016.Amgen makes up approximately 1.65% of Dsc Advisors’s portfolio.

Other Hedge Funds, Including , D. E. Shaw boosted its stake in AMGN in the latest quarter, The investment management firm added 446,710 additional shares and now holds a total of 2,973,952 shares of Amgen which is valued at $514,553,175. Amgen makes up approx 1.06% of D. E. Shaw’s portfolio.Taylor Cottrill Erickson Associates boosted its stake in AMGN in the latest quarter, The investment management firm added 3,030 additional shares and now holds a total of 39,930 shares of Amgen which is valued at $6,885,130. Amgen makes up approx 1.90% of Taylor Cottrill Erickson Associates’s portfolio.Wesbanco Bank Inc reduced its stake in AMGN by selling 939 shares or 1.01% in the most recent quarter. The Hedge Fund company now holds 91,894 shares of AMGN which is valued at $15,845,282. Amgen makes up approx 0.91% of Wesbanco Bank Inc’s portfolio.Connable Office Inc reduced its stake in AMGN by selling 228 shares or 1.7% in the most recent quarter. The Hedge Fund company now holds 13,210 shares of AMGN which is valued at $2,294,049. Amgen makes up approx 0.62% of Connable Office Inc’s portfolio.Lmr Partners Llp boosted its stake in AMGN in the latest quarter, The investment management firm added 1,606 additional shares and now holds a total of 10,952 shares of Amgen which is valued at $1,884,073. Amgen makes up approx 0.28% of Lmr Partners Llp’s portfolio.

Amgen closed down -0.21 points or -0.12% at $170.63 with 2,013,680 shares getting traded on Wednesday. Post opening the session at $169.78, the shares hit an intraday low of $169.2 and an intraday high of $171.44 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

On the company’s financial health, Amgen reported $2.84 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $2.74. The company had revenue of $5688.00 million for the quarter, compared to analysts expectations of $5579.33 million. The company’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.57 EPS.

Many Wall Street Analysts have commented on Amgen. Amgen was Initiated by Bernstein to “Mkt Perform” on Jun 29, 2016.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Leave a Reply

Amgen - Is it time to Sell?

Top Brokerage Firms are advising their investors on Amgen. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.